A PYMNTS Company

Takeda To Divest Products To Brazil’s Hypera For $825M

By  |  March 2, 2020

Brazil’s Hypera Pharma announced on Monday, March 2, that it has signed a contract to buy a portfolio of 18 pharmaceutical products from Japan’s Takeda for US$825 million, reported Reuters.  

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The portfolio includes the painkiller Neosaldina, as well as drugs Dramin and Nesina. Hypera Pharma claims that following the transaction it will become Brazil’s top pharma company.

    Hypera has secured a 3.5 billion reais (US$779.49 million) credit line to pay for the acquisition, which is contingent on antitrust authorities and shareholder approval of the deal.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.